Share this via
The fund is being launched at a flat ₹10 Net Asset Value and will be available for a limited period during its NFO from July 14
As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent and certainother related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S.
Get over your FOMO of knowing what's happening. Never miss what matters to you!
